MIR1285-1

Summary

MIR1285-1 (microRNA 1285-1, HGNC:35277) is a microRNA gene on chromosome 7q21.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100302218 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:35277
Approved symbol	MIR1285-1
Name	microRNA 1285-1
Location	7q21.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-1285-1
Ensembl gene	ENSG00000221520
Ensembl biotype	miRNA
Entrez	100302218
RNAcentral	URS000075B442 — miRNA, 84 nt, 4 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000408593

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000408593 — 1 exons

Exon	Start	End
ENSE00001565228	92204015	92204098

Expression profiles

Bgee: expression breadth ubiquitous, 113 present calls, max score 86.21.

Top tissues by expression

113 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	86.21	gold quality
duodenum	UBERON:0002114	84.44	gold quality
skeletal muscle tissue	UBERON:0001134	83.38	gold quality
placenta	UBERON:0001987	82.30	gold quality
prefrontal cortex	UBERON:0000451	79.55	gold quality
smooth muscle tissue	UBERON:0001135	79.46	gold quality
bone marrow	UBERON:0002371	79.20	gold quality
vermiform appendix	UBERON:0001154	79.17	gold quality
granulocyte	CL:0000094	78.84	gold quality
fundus of stomach	UBERON:0001160	78.31	gold quality
calcaneal tendon	UBERON:0003701	78.31	gold quality
right lung	UBERON:0002167	77.92	gold quality
blood	UBERON:0000178	77.59	gold quality
endometrium	UBERON:0001295	77.48	gold quality
right ovary	UBERON:0002118	77.29	gold quality
ectocervix	UBERON:0012249	77.28	gold quality
monocyte	CL:0000576	77.09	gold quality
ovary	UBERON:0000992	76.70	gold quality
left ovary	UBERON:0002119	76.70	gold quality
muscle of leg	UBERON:0001383	76.29	gold quality
stomach	UBERON:0000945	76.07	gold quality
ascending aorta	UBERON:0001496	76.04	gold quality
thoracic aorta	UBERON:0001515	75.83	gold quality
body of stomach	UBERON:0001161	75.76	gold quality
left coronary artery	UBERON:0001626	75.72	gold quality
gastrocnemius	UBERON:0001388	75.37	gold quality
body of pancreas	UBERON:0001150	75.36	gold quality
pancreas	UBERON:0001264	74.95	gold quality
tibial artery	UBERON:0007610	74.88	gold quality
lymph node	UBERON:0000029	74.85	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.81

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 11)

• miR-1285 modulates a novel molecular target and provides new insights into potential mechanisms of renal cell carcinoma oncogenesis. (PMID:22294552)
• Human miR-1285-3p could directly repress JUN oncogene expression in hepatocellular carcinoma cells. (PMID:25230788)
• Data show that four cardiac fibroblast-derived microRNAS miR-660-3p, miR-665, miR-1285-3p and miR-4491 were found significantly upregulated in heart and plasma during heart failure. (PMID:26683101)
• The combination of plasma miR-324-3p and miR-1285 could further improve the diagnostic accuracy of lung squamous cell carcinoma (LSCC). (PMID:27517633)
• miR-1285 suppressed cell proliferation as well as increased the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine; miR-1285 inhibited pancreatic cancer cell migration and invasion (PMID:28253715)
• our data suggest that miR-1285-5p functions as a tumor promoter in the development of non-small-cell lung carcinoma by targeting Smad4 and CDH1, indicating a novel therapeutic strategy for non-small-cell lung carcinoma patients. (PMID:28631567)
• MiR-1285-3p was down regulated in osteosarcoma tissues and cell lines and reduction of miR-1285-3p expression predicted a poor overall survival of osteosarcoma patients. Ectopic expression of miR-1285-3p inhibited osteosarcoma cell proliferation, colony formation and invasion. (PMID:31006663)
• Methylation dependent microRNA 1285-5p and sterol carrier proteins 2 in type 2 diabetes mellitus (PMID:31407919)
• Data showed the tumor-suppressive role of miR-1285 and detailed its mechanism of action in breast cancer. Its overexpression significantly inhibited cell proliferation in breast cancer cells regardless of the tumor subtype. Also, miR-1285 was found to regulate TMEM194A expression by binding to its 3’-UTR. (PMID:31854049)
• Circular RNA hsa_circ_0000376 Participates in Tumorigenesis of Breast Cancer by Targeting miR-1285-3p. (PMID:32462972)
• Repression of Smad4 by MicroRNA-1285 moderates TGF-beta-induced epithelial-mesenchymal transition in proliferative vitreoretinopathy. (PMID:34383767)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.